CA
NZ
UK
AU
IND
US
• The NBS Manufacturing PMI rose to 50.3 in June from 50.0 in May, beating the 50.1 consensus forecast and marking a third straight month above the 50 expansion threshold.
• Headline inflation eased to 2.3% year-over-year in June, down from 2.6% in May and below the 2.6% market consensus.
• $50 Million in Upfront Proceeds: Pyxis Oncology secured immediate gross proceeds through a newly announced private placement financing.
• CRL Limited to Manufacturing, Not Clinical Data: The FDA's rejection centered solely on unresolved CMC issues at a third-party facility, with no new clinical or safety concerns raised.
• Primary Endpoint Missed: Fasedienol showed a -9.5 SUDS change versus -11.4 for placebo, a statistically insignificant difference (p=0.427).
• $21 Million Secured: Decoy Therapeutics closed a private placement at $5.91 per share with a dedicated healthcare investor.
• Primary Endpoint Met With Strong Effect Size: Epcoritamab plus lenalidomide significantly improved PFS over R-GemOx in relapsed/refractory DLBCL.
• $100 Million Raised at $20.00 Per Share: Nuvectis priced a public offering to bolster its balance sheet and fund pipeline expansion.
• Seeking Global Endpoint Harmonization: OS Therapies requested an FDA Type B meeting to align OST-HER2 trial endpoints with international (FDA-EMA) standards.
• Manageable Safety Profile: Treatment-related adverse events were limited to Grade 1–2 severity, with no dose-limiting toxicities reported.
Please wait processing your request...